First glyphosate-cancer trial appeal could give Bayer ‘significant leverage’ in settlement talks with over 50,000 plaintiffs

This article or excerpt is included in the GLP’s daily curated selection of ideologically diverse news, opinion and analysis of biotechnology innovation.

A California appeals court on [June 2] will hear oral arguments in agrochemical giant Monsanto’s bid to toss a $78.5 million award stemming from the first trial over the company’s popular “Roundup” weed killer ….

Monsanto, which was acquired by Bayer in 2018, will ask a three-judge panel to enter judgment in their favor or to order a new trial. The court’s decision will have a major impact on ongoing settlement discussions involving over 50,000 plaintiffs who claim they developed cancer from exposure to the chemical glyphosate in herbicides like Roundup.

The $289 million verdict in that trial (subsequently reduced to $78.5 million) and other verdicts that followed battered Bayer’s stock price, and whether or not the verdict survives the appeal will give significant leverage to plaintiffs or Bayer depending on the outcome.

Related article:  Viewpoint: Bayer 'open for looting' as company battles 11,000 glyphosate-cancer lawsuits

Read the original post

Share via
News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.
Send this to a friend